Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in ...

Anne Zimmerman, editor-in-chief of the Columbia University online journal, <a href=" target="_blank">Voices in Bioethics ...

In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a ...

Pivotal trial design can make or break a new therapy's commercial viability. This article explores how choosing the right ...

Longer time horizons and therapeutic area expertise make philanthropy venture capital an attractive option for ...

Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its ...

Job rotations provide an opportunity for promising, high-potential employees to grow and learn new parts of the business.

Part two of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...